LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Bruno Sangro, J. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang–Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, G. Chen, Jaclyn Neely, Marina Tschaika, Thomas Yau (2020). LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. , 31, DOI: https://doi.org/10.1016/j.annonc.2020.04.078.
